KR20120022766A - 무정형 알파-(n-술폰아미도)아세트아미드 화합물의 생체이용가능한 캡슐 조성물 - Google Patents

무정형 알파-(n-술폰아미도)아세트아미드 화합물의 생체이용가능한 캡슐 조성물 Download PDF

Info

Publication number
KR20120022766A
KR20120022766A KR1020117024036A KR20117024036A KR20120022766A KR 20120022766 A KR20120022766 A KR 20120022766A KR 1020117024036 A KR1020117024036 A KR 1020117024036A KR 20117024036 A KR20117024036 A KR 20117024036A KR 20120022766 A KR20120022766 A KR 20120022766A
Authority
KR
South Korea
Prior art keywords
peg
capsule
tpgs
crystallization inhibitor
trifluoropentanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117024036A
Other languages
English (en)
Korean (ko)
Inventor
사킨 찬드란
라제쉬 바불랄 간디
자콴 칼라니 레본스
로버트 케빈 페론
크리스토퍼 피. 프라이스
크리쉬나스와미 스리니바스 라가반
이스마트 울라
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20120022766A publication Critical patent/KR20120022766A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020117024036A 2009-04-14 2010-04-13 무정형 알파-(n-술폰아미도)아세트아미드 화합물의 생체이용가능한 캡슐 조성물 Withdrawn KR20120022766A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16906109P 2009-04-14 2009-04-14
US61/169,061 2009-04-14

Publications (1)

Publication Number Publication Date
KR20120022766A true KR20120022766A (ko) 2012-03-12

Family

ID=42235859

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117024036A Withdrawn KR20120022766A (ko) 2009-04-14 2010-04-13 무정형 알파-(n-술폰아미도)아세트아미드 화합물의 생체이용가능한 캡슐 조성물

Country Status (14)

Country Link
US (1) US8252821B2 (cg-RX-API-DMAC7.html)
EP (1) EP2419090B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012524092A (cg-RX-API-DMAC7.html)
KR (1) KR20120022766A (cg-RX-API-DMAC7.html)
CN (1) CN102395361A (cg-RX-API-DMAC7.html)
AR (1) AR076305A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010236602A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1015483A2 (cg-RX-API-DMAC7.html)
CA (1) CA2758847A1 (cg-RX-API-DMAC7.html)
EA (1) EA201101286A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011010514A (cg-RX-API-DMAC7.html)
NZ (1) NZ595335A (cg-RX-API-DMAC7.html)
TW (1) TW201041609A (cg-RX-API-DMAC7.html)
WO (1) WO2010120755A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1465861T3 (da) 2001-12-20 2009-08-31 Bristol Myers Squibb Co Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
CN102577156B (zh) 2009-10-02 2016-01-20 Lg电子株式会社 用于下行链路参考信号的发送方法和装置
CN103402543B (zh) * 2010-12-16 2015-09-16 德克萨斯州立大学董事会 用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法
AU2012250050B2 (en) 2011-04-28 2017-04-06 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
EP3927324A1 (en) * 2019-02-22 2021-12-29 Janssen Pharmaceutica NV Pharmaceutical formulations
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
EP4199911A1 (en) * 2020-08-21 2023-06-28 JANSSEN Pharmaceutica NV Pharmaceutical formulations comprising a malt1 inhibitor and a mixture of polyethylene glycol with a fatty acid

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
SK282833B6 (sk) * 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
BR9710752A (pt) 1996-07-22 1999-08-17 Monsanto Co Inbidores de metaloprotease de sulfonamida de tiol
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するTNF―α産生抑制剤
ATE280152T1 (de) 1999-01-27 2004-11-15 Wyeth Corp Acetylenische sulfonamid-thiol-tace-inhibitoren
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
CN1348442A (zh) 1999-02-26 2002-05-08 默克公司 新的磺胺化合物及其应用
EP1435910B9 (en) * 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
DK1465861T3 (da) 2001-12-20 2009-08-31 Bristol Myers Squibb Co Alpha-(N-sulfonamid)acetamidderivater som beta-amyloidhæmmere
AU2004230844B2 (en) * 2003-03-31 2010-12-09 Wyeth Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
EP1680406A1 (en) 2003-10-29 2006-07-19 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
AU2005237580B2 (en) * 2004-04-28 2011-06-16 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
RU2378258C2 (ru) 2004-07-13 2010-01-10 Ф. Хоффманн-Ля Рош Аг Производные сульфонамида
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
BRPI0519036A2 (pt) * 2004-12-14 2008-12-23 Wyeth Corp mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6
CA2641013A1 (en) * 2006-02-17 2007-08-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
RU2008131051A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
WO2007103683A2 (en) * 2006-03-01 2007-09-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US20110059940A1 (en) 2008-05-08 2011-03-10 Bristol- Myers Squibb Company 2-Aryl Glycinamide Derivatives
JP2012520875A (ja) 2009-03-19 2012-09-10 ブリストル−マイヤーズ スクイブ カンパニー ベータアミロイドペプチド産生阻害剤としての新規アルファ−(n−スルホンアミド)アセトアミド化合物
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
NZ595335A (en) 2013-03-28
AU2010236602A1 (en) 2011-10-13
BRPI1015483A2 (pt) 2016-04-26
MX2011010514A (es) 2011-11-29
EA201101286A1 (ru) 2012-04-30
CA2758847A1 (en) 2010-10-21
US8252821B2 (en) 2012-08-28
US20100260837A1 (en) 2010-10-14
CN102395361A (zh) 2012-03-28
JP2012524092A (ja) 2012-10-11
WO2010120755A1 (en) 2010-10-21
EP2419090B1 (en) 2013-02-13
TW201041609A (en) 2010-12-01
AR076305A1 (es) 2011-06-01
EP2419090A1 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
US8252821B2 (en) Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
ES2950995T3 (es) Un comprimido que comprende un derivado de metoxiurea y partículas de manitol
CN101069685B (zh) 固体口服剂型药物
CN101636152A (zh) 含有西洛他唑的控释制剂及其制备方法
CA2852618C (en) Pharmaceutical composition
BRPI0710405A2 (pt) comprimido de racecadotril, processo de preparação de um comprimido de racecadotril e uso de racecadotril
EP2419086B1 (en) Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound
JP5021887B2 (ja) アゼチジン誘導体に基づく医薬組成物
JP5775463B2 (ja) 溶出安定性製剤
ES2674811T3 (es) Composiciones estables de fesoterodina
ES2558204T3 (es) Formulaciones de comprimido bicapa de flurbiprofeno y glucosamina
WO2004052342A1 (en) A new oral immediated release dosage form
JP6116847B2 (ja) シクロデキストリンとの混合体を含有する錠剤
US20260069569A1 (en) Ebselen containing oral dosage forms
US20250352482A1 (en) Amorphous dosage form containing ebselen
WO2024043842A1 (en) Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
KR20240155526A (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
JP5946135B2 (ja) トリクロルメチアジドおよび結晶セルロースを含有する固形製剤
US20160022818A1 (en) Pharmaceutical formulation comprising lipase inhibitor having increased dissolution rate and reduced side effects, and method for preparing same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111013

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid